Wanbury Peer Comparison

NSE: WANBURY | BSE: 524212

₹181.93

₹7.77 (4.46%)

As on 29-Oct-2026IST

Market cap

₹631 Cr

Revenue (TTM)

₹653 Cr

P/E Ratio

11.3

P/B Ratio

4.3

Div. Yield

0 %

Edit

	Wanbury	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Market cap (₹ Cr)	631	31,226	32,597	30,701	25,835
Revenue (₹ Cr)	653	3,564	1,593	9,779	1,936
Net Profit (₹ Cr)	55.89	414.00	438.64	-270.51	288.22
Net Margin (%)	8.55	11.23	27.16	-2.71	14.79
RoE (%)	48.51	8.38	25.02	-2.55	29.77
Price to Earnings	11.30	76.35	74.23	--	89.64
Price-To-Book	4.30	6.20	17.55	3.77	19.25

Income Statement (₹ Cr)

	Wanbury	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Operating Revenue	650.27	3,373.00	1,339.37	8,869.08	1,753.96
Total Income	832.41	3,510.00	1,380.95	9,111.51	1,762.66
Total Expenditure	724.71	2,747.00	858.97	7,976.59	1,354.69
EBITDA	-74.44	626.00	480.40	892.49	399.26
Depreciation	14.31	227.00	35.99	831.24	45.26
EBIT	-88.76	399.00	444.41	61.25	354.00
Interest	29.98	213.00	3.27	340.80	42.17
Other Income	182.14	137.00	41.59	242.43	8.70
Exceptional Items	-3.60	-85.00	--	-196.14	--
Profit before Tax	59.80	238.00	482.73	-176.06	320.53
Provision for Tax	-6.33	39.00	126.36	149.88	73.80
Profit after Tax	66.13	199.00	356.37	-325.94	246.74

	Wanbury	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Shareholder's Funds	144.45	4,940.00	1,653.56	8,162.62	1,288.82
Minority Interest	0.00	341.00	57.19	--	0.00
Non-Current Liabilities	157.98	1,235.00	42.40	4,529.41	189.02
Current Liabilities	201.04	1,622.00	230.81	4,874.74	835.87
Total Liabilities	517.67	8,578.00	1,983.96	17,723.32	2,326.71

	Wanbury	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Non-Current Assets	264.91	5,441.00	1,102.69	10,258.66	631.90
Current Assets	238.56	2,606.00	881.27	7,308.11	1,681.81
Total Assets	517.67	8,578.00	1,983.96	17,723.32	2,326.71
Total Debt*	215.45	2,125.00	26.49	5,495.48	259.37
Net Current Assets	37.52	984.00	650.46	2,433.37	845.94
Contingent Liabilities	121.89	768.26	17.25	95.72	19.09

	Wanbury	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Cash From Operating Activities	31.53	390.00	292.17	1,652.60	205.05
Cash Flow from Investing Activities	-56.40	-241.00	-265.94	-826.03	-409.72
Cash from Financing Activities	22.42	-54.00	4.10	-38.98	283.07
Net Cash Inflow / Outflow	-2.45	95.00	30.33	787.59	78.39

	Wanbury	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
ROCE (%)	30.31	6.79	32.42	1.24	29.22
ROE (%)	67.87	4.29	24.08	-4.04	27.84
ROA (%)	14.53	2.53	20.17	-1.98	13.11
EBIT Margin (%)	16.56	22.62	38.97	12.80	23.26
Net Margin (%)	7.95	5.67	25.81	-3.58	14.00
Cash Profit Margin (%)	12.27	10.98	29.29	4.80	7.71

	Wanbury	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Revenue Growth (%)	8.47	11.99	33.02	-3.08	36.57
EBIT Growth (%)	34.76	67.69	109.63	-28.15	52.29
Net Profit Growth (%)	116.62	449.12	122.15	-457.66	83.64
EPS Growth (%)	103.18	553.20	348.92	-456.91	71.44
Book Value Growth (%)	179.06	13.47	26.03	0.33	144.31

	Wanbury	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Price / Earnings	11.76	89.54	58.79	0.00	51.69
Price / Book Value	5.42	3.87	12.69	2.24	10.14
Dividend Yield (%)	0.00	0.00	0.10	0.00	0.19
EV/EBITDA	9.15	27.45	39.75	19.72	31.05
Market Cap (₹ Cr)	777.59	19,071.62	20,944.75	18,108.89	12,753.19

	Wanbury	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Debt to Equity	1.50	0.43	0.02	0.68	0.21
Short term debt to equity ratio	0.19	0.09	0.02	0.09	0.05
Current Ratio	1.19	1.61	3.82	1.50	2.01
Quick Ratio	0.93	1.06	2.82	0.87	1.14
Interest Coverage	3.00	2.12	148.71	0.48	8.60

	Wanbury	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Debtors to sales (%)	22.03	17.43	27.07	24.33	29.00
Asset Turnover	1.44	0.49	0.76	0.64	2.01
Receivable days	71.68	58.75	88.98	78.20	40.13
Inventory Days	24.59	75.82	56.04	93.30	60.29
Payable days	162.17	186.21	99.95	226.14	232.47
Cash Conversion Cycle	-65.90	-51.64	45.07	-54.64	-132.04

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.